RE: Exciting few days and weeks17 Mar 2021 08:39
The profile of the CDX as an antibody based treatment AND its additional benefits being suggested to be combining with other more toxic treatments to help lower the overall toxicity of the treatment potentially help make failed drugs become viable again suggests toxicity is very very low and has a tiny chance of failure. That phase 1 covered.
Efficacy... phase 2a running simultaneously, we know it works effectively on the ApbHC Mice.
Chances of failure during phase 1and 2a simulate Eli’s testing very low. Imo.
SAFE HEMO CAR T we have bossed the safety profile of its application solving the scientific challenge of controlling the CAR T cells.
Vlads a genius! End of!